This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Continuous learning is not just an option but a responsibility that every healthcare professional must shoulder
Imaginant offers a unique measurement capability through its PELT coating thickness gauges
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Subscribe To Our Newsletter & Stay Updated
